The stock price of TransCode Therapeutics Inc (NASDAQ: RNAZ) has plunged by -5.77 when compared to previous closing price of 0.52, but the company has seen a -56.25% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-27 that First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded enrollment No significant safety or dose limiting toxicities have been reported BOSTON, March 27, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138.
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
The 36-month beta value for RNAZ is also noteworthy at 1.45. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of RNAZ on March 31, 2025 was 6.72M shares.
RNAZ’s Market Performance
RNAZ stock saw a decrease of -56.25% in the past week, with a monthly decline of -80.56% and a quarterly a decrease of -86.08%. The volatility ratio for the week is 18.66%, and the volatility levels for the last 30 days are 23.16% for TransCode Therapeutics Inc (RNAZ). The simple moving average for the last 20 days is -53.64% for RNAZ stock, with a simple moving average of -96.10% for the last 200 days.
RNAZ Trading at -89.93% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.26% of loss for the given period.
Volatility was left at 23.16%, however, over the last 30 days, the volatility rate increased by 18.66%, as shares sank -75.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -84.64% lower at present.
During the last 5 trading sessions, RNAZ fell by -56.25%, which changed the moving average for the period of 200-days by -98.85% in comparison to the 20-day moving average, which settled at $1.0570. In addition, TransCode Therapeutics Inc saw -85.46% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -19.47 for the present operating margin
- 0.44 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -19.82. The total capital return value is set at -8.88. Equity return is now at value -490.03, with -210.77 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -103.97. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -181.32.
Currently, EBITDA for the company is -17.97 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 12.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.
Conclusion
In summary, TransCode Therapeutics Inc (RNAZ) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
